Dr. David Page, mentioned in today's New Bavi-Trials PR re: the upcoming Ph.2 Triple- MBC trial that “originated from Peregrine's ongoing collaboration with Memorial Sloan Kettering” - note Dr. Page's prior work with Dr. Jedd Wolchok, chief of Mem.Sloan's Melanoma & Immunotherapeutics Service who “investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions”….
From today's (1-11-16) PR, “Peregrine Provides Update on Planned Expansion of Bavi Clinical Pgm in Lung, Breast and Other Cancers”… PLANNED TRIALS... #4. Phase II Trial in Early Stage TNBC in Combination with Chemotherapy Peregrine is planning to initiate a Phase II trial of bavituximab in combination with neoadjuvant chemotherapy in early stage TNBC. The primary endpoint of this study is to determine the pathologic complete response rate (pCR), an accepted surrogate endpoint in early stage TNBC. The concept for this neoadjuvant setting trial, which will be conducted at a few select U.S. sites, originated from Peregrine's ongoing collaboration with Memorial Sloan Kettering Cancer Center (MSKCC). The company has filed a study protocol to its existing bavituximab IND application in the U.S. and is currently working to open clinical trial sites, including one that will be led by David B. Page, M.D., at the Providence Cancer Center in Oregon. http://tinyurl.com/zhdy37a
FROM DR. PAGE's BREAST CANCER RES. FOUNDATION (BCRF) PROFILE: David B. Page, MD, is a medical oncologist at Providence Portland Medical Center in Portland, Oregon. Dr. Page first became fascinated with cancer biology & immunology as an undergraduate at the Univ. of Chicago and later studied under the mentorship of medical oncologist Dr. Jedd Wolchok, a pioneer in immunotherapy, at Memorial Sloan Kettering Cancer Center. Alongside Dr. Wolchok, Dr. Page treated numerous patients with metastatic melanoma, a usually fatal skin cancer, some who have been cured of cancer and are still living today as a result of immunotherapy. As a fellow, Dr. Page developed several investigator-initiated clinical trials evaluating immunotherapy in breast cancer, including a pilot study... http://www.bcrfcure.org/researchers/david-page
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/qxu4w2x ”The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said (Mem.Sloan’s) Dr. Jedd D. Wolchok.
= = = = = = = = = = 1-11-16/PR: Update on 4 New Bavi Clinical Trials (Lung/AZN, Breast/1Co./1MSKCC, Other Cancers/AZN). SUNRISE estimates: Interim1=Early'16, Interim2=Mid'16, FinalUnblinding=End'16… http://tinyurl.com/zhdy37a
9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn ...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”
7-14-15 Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/nw2v5u6 ...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”
Market Data 
Markets 
AI
